Inhibrx, a Phase 1 biotech developing single domain antibodies for cancer and rare diseases, raised $119 million by offering 7 million shares at $17, the midpoint of the range of $16 to $18. The company offered 1 million more shares than anticipated.
Inhibrx plans to list on the Nasdaq under the symbol INBX. Jefferies, Evercore ISI and Credit Suisse acted as lead managers on the deal.
